Research programme: PCSK9 inhibitors - Liphorus Pharmaceuticals

Drug Profile

Research programme: PCSK9 inhibitors - Liphorus Pharmaceuticals

Latest Information Update: 11 Dec 2014

Price : $50

At a glance

  • Originator Liphorus Pharmaceuticals
  • Developer Clinical Research Institute of Montreal
  • Class Small molecules
  • Mechanism of Action PCSK9 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Research Hypercholesterolaemia

Most Recent Events

  • 11 Dec 2014 Early research in PCSK9 inhibitors for the treatment of Hypercholesterolaemia is ongoing in Canada
  • 02 Jul 2014 European patent no. EP 2348106 B1 granted to Adaerata Limited Partnership
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top